Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.67 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | MDH1 | P40925 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812742 | 0.99 | PTPN11 (0.68) | PTPN11PTPROCNR2RARBRARA | |
| SCHEMBL1812532 | 0.95 | PTPN11 (0.63) | PTPN11PTPROCNR2RARBRARA | |
| SCHEMBL1814320 | 0.94 | PTPN11 (0.62) | PTPN11PTPROCNR2RARBRARA | |
| SCHEMBL1812533 | 0.93 | PTPN11 (0.60) | PTPN11PTPROCNR2SOAT1 | |
| SCHEMBL1814294 | 0.92 | PTPN11 (0.59) | PTPN11PTPROCNR2PPARGPPARA | |
| SCHEMBL1811147 | 0.92 | PTPN11 (0.56) | PTPN11PTPROCNR2RARBRARA | |
| SCHEMBL1812712 | 0.91 | PTPN11 (0.60) | PTPN11PTPROCNR2STAT3 | |
| SCHEMBL1812105 | 0.91 | PTPN11 (0.55) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656207 | 0.90 | PTPN11 (0.56) | PTPN11PTPROCNR2RARBRARA | |
| SCHEMBL1812993 | 0.89 | PTPN11 (0.80) | PTPN11PTPROCNR2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | claimed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1756081-A1 | 1,1'-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-02-28 | — | — | EP | claimed |
| WO-2005097773-A1 | 1,1’-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | claimed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1756081-A1 | 1,1'-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005097773-A1 | 1,1’-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | PTPN11 38/4885PTPRO 4/4885CNR2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.